Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec

Saint-Herblain 44805

2 studies enrolling now · 9 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Extensive Stage Small-cell Lung Cancer, Extensive-Stage Small-Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Obesity, Overweight, Small-Cell Lung Cancer, Small-cell Lung Cancer, Type 2 Diabetes

Studies at this site

• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — Recruiting now
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — Recruiting now
• Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide — Running, not enrolling
• A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight — Running, not enrolling
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) — Completed
• Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) — Completed
• A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight — Completed
• A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo — Completed
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling